Hepatic vascular lesions associated with dacarbazine treatment

M A GREENSTONE, PAULINE M DOWD, D P MIKHAILIDIS, P J SCHEUER

Abstract

Dacarbazine is widely used in the treatment of melanoma. Transient abnormalities of liver function tests are well-recognized side effects of the drug, but acute liver failure due to vascular occlusion in patients receiving single-agent chemotherapy with dacarbazine has been noted only rarely. Two cases are reported in which hepatic vascular lesions developed during treatment with dacarbazine and were confirmed at necropsy.

Hepatic vascular occlusion due to treatment with dacarbazine may be less rare than was previously thought. Greater caution may be needed when dacarbazine is prescribed, particularly as an adjuvant agent in stage I and II disease.

Introduction

Dacarbazine (dimethyl-triazeno-imidazole-carboxamide) has been widely used in the treatment of stage III melanoma and in trials of adjuvant chemotherapy in patients with stage I and II disease with a poor prognosis. We report two cases in which hepatic vascular lesions occurred during dacarbazine treatment.

Case reports

CASE 1

A 53-year-old Caucasian man developed histologically proved lymph-node metastases five years after wide excision of primary melanoma. In April 1978 he began treatment with dacarbazine (250 mg/m² daily for five days). He was also taking amitriptyline (Lentizol) 50 mg at night and chlorpromazine as an antiemetic. Apart from transient fever on the fifth day, he tolerated treatment well. One month later he was readmitted for a second course of dacarbazine. He was well, and clinical examination, full blood count, urea and electrolyte concentrations, and liver function tests were all normal. His medication was as before. He remained well until the fourth day of treatment, when he developed acute abdominal pain and hepatic tenderness. He deteriorated with confusion, jaundice, and hypotension. Results of liver function tests became extremely abnormal (aspartate transaminase activity 1780 U/l, alkaline phosphatase activity 148 IU/l, total bilirubin 77 µmol/l (4.5 mg/100 ml), and he developed prolonged prothrombin and partial thromboplastin times, hypoglycaemia, and a profound metabolic acidosis. A peripheral blood film showed only mild neutrophilia (74% of 139 x 10⁹/l), whereas a differential white cell count two days earlier had shown eosinophilia of 17% of 7 x 10⁹/l. Blood cultures were repeatedly negative. Despite vigorous supportive treatment he died 72 hours later.

At necropsy the liver had a mottled red appearance and irregular areas of necrosis were seen. The main hepatic and portal veins were patent. On microscopy recent infarcts were associated with fresh thrombi in hepatic vein branches. Vein walls and portal tracts were infiltrated with lymphocytes and eosinophils. There was a microscopically extensive metastasis in one lung.

CASE 2

A 46-year-old Caucasian man was treated with dacarbazine 500 mg intravenously daily for five days for metastatic melanoma. He tolerated the first course of treatment well but on the third day of the second course developed clinical and laboratory manifestations of acute hepatic necrosis. There was no clinical evidence of drug hyper-
sensitivity (for example, skin eruption), but eosinophil counts were not available. He died about 72 hours later. No other cytotoxic agents had been administered.

Necropsy disclosed no thrombi in major vessels but showed recent hepatic infarcts, and thrombi were seen in portal and hepatic vein branches on microscopy (figure). Metastases were present in the heart, lung, pancreas, and kidneys.

Recently formed thrombus (T) in hepatic vein branch (V). Haematoxylin and eosin × 180 (original magnification).

Discussion

Transient abnormalities of liver function tests are recognised side effects of dacarbazine treatment. To our knowledge acute liver failure due to vascular occlusion in patients receiving single-agent chemotherapy with dacarbazine has been reported in only one case. Our patients showed broadly similar clinical, laboratory, and histological features. The temporal relation to dacarbazine treatment, the absence of any other identifiable cause, and the histological dissimilarity to the rare hepatic lesions attributed to chlorpromazine and amitryptiline incriminate dacarbazine. A synergistic adverse drug reaction cannot, however, be excluded. The eosinophilia in case I, which suggests a drug reaction, was transient and preceded clinical deterioration. Eosinophil counts during each course of treatment may therefore be valuable in the early detection of liver damage.

One of us (PJS) reviewed the histology of a further patient receiving dacarbazine in whom hepatic vein thrombosis had led to the Budd-Chiari syndrome. We are also aware of five other deaths after hepatic vascular occlusions in patients receiving dacarbazine as part of multiple-agent chemotherapy (J S Goodall, Miles Laboratories, personal communication). We suggest that this complication of dacarbazine treatment may not be as rare as was previously thought. In view of this greater caution may be needed when considering the use of dacarbazine, especially as an adjuvant agent in stage I and II disease.

We thank Dr J D Everall for permission to publish the clinical details; Dr A Levene for access to postmortem material in case 1; the Ministry of Defence for permission to publish the details of case 2; and the late Dr J S Goodall of Miles Laboratories for his help.

References


(Accepted 18 March 1981)

Retinal vasculitis in rheumatoid arthritis

M F R MARTIN, D G I SCOTT, C GILBERT, P A DIEPPE, D L EASTY

Abstract

A woman with exacerbation of severe rheumatoid arthritis developed lesions compatible with retinal vasculitis. Laboratory studies confirmed the diagnosis, and the rapid clinical improvement that accompanied a fall in circulating immune complexes suggested that the vasculitis was a direct consequence of the rheumatoid disease.

From these observations retinal vasculitis should probably be sought in any patient with rheumatoid disease and the vasculitis added to the list of ocular complications of rheumatoid arthritis.

Introduction

We report a case of severe rheumatoid arthritis with high concentrations of circulating immune complexes, nailfold vasculitis, and transient lesions consistent with retinal vasculitis.

Case history

A 51-year-old white woman with a history of pulmonary tuberculosis developed rheumatoid arthritis in 1965; this was complicated by recurrent scleritis (1971, 1976), keratoconjunctivitis sicca (1976), sensory peripheral neuropathy (1971), and rheumatoid nodules. She presented in September 1979 with an exacerbation of the rheumatoid arthritis while taking penicillamine 500 mg and prednisolone 5 mg daily. She reported increased joint pain and stiffness, night sweats, weight loss, and diminished visual acuity. Examination showed active